Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kelly Wayne Furness is active.

Publication


Featured researches published by Kelly Wayne Furness.


Bioorganic & Medicinal Chemistry Letters | 2003

Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

Thomas A. Engler; Kelly Wayne Furness; Sushant Malhotra; Concha Sanchez-Martinez; Chuan Shih; Walter Xie; Guoxin Zhu; Xun Zhou; Scott Eugene Conner; Margaret M. Faul; Kevin A. Sullivan; Stanley P. Kolis; Harold B. Brooks; Bharvin Patel; Richard M. Schultz; Tammy B. DeHahn; Kashif Kirmani; Charles D. Spencer; Scott A. Watkins; Eileen L. Considine; Jack Dempsey; Catherine A. Ogg; Nancy B. Stamm; Bryan D. Anderson; Robert M. Campbell; Vasu Vasudevan; Michelle L. Lytle

The synthesis and CDK inhibitory properties of a series of indolo[6,7-a]pyrrolo[3,4-c]carbazoles is reported. In addition to their potent CDK activity, the compounds display antiproliferative activity against two human cancer cell lines. These inhibitors also effect strong G1 arrest in these cell lines and inhibit Rb phosphorylation at Ser780 consistent with inhibition of cyclin D1/CDK4.


Tetrahedron Letters | 2003

An improved method for direct conversion of heteroaryl-aldehydes to heteroaryl-acetonitriles

Thomas A. Engler; Kelly Wayne Furness; Sushant Malhotra; Clive Gideon Diefenbacher; Joshua Ryan Clayton

Abstract Treatment of heteroaryl-aldehydes with diethyl cyanophosphonate in the presence of a catalytic amount of LiCN affords phosphorylated cyanohydrins which are reduced in situ with SmI 2 to give heteroaryl-acetonitriles in generally good overall yields (50–100%). The generality of the process is demonstrated.


ACS Medicinal Chemistry Letters | 2018

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor

Aruna Wijeratne; Junpeng Xiao; Christopher T. Reutter; Kelly Wayne Furness; Rebecca Leon; Mohammad Zia-Ebrahimi; Rachel N. Cavitt; John M. Strelow; Robert D. Van Horn; Sheng-Bin Peng; David Anthony Barda; Thomas A. Engler; Michael J. Chalmers

The KRASG12C protein product is an attractive, yet challenging, target for small molecule inhibition. One option for therapeutic intervention is to design small molecule ligands capable of binding to and inactivating KRASG12C via formation of a covalent bond to the sulfhydryl group of cysteine 12. In order to better understand the cellular off-target interactions of Compound 1, a covalent KRASG12C inhibitor, we have completed a series of complementary chemical proteomics experiments in H358 cells. A new thiol reactive probe (TRP) was designed and used to construct a cellular target occupancy assay for KRASG12C. In addition, the thiol reactive probes allowed us to profile potential off-target interactions of Compound 1 with over 3200 cysteine residues. In order to complement the TRP data we designed Compound 2, an alkyne containing version of Compound 1, to serve as bait in competitive chemical proteomics experiments. Herein, we describe and compare data from both the TRP and the click chemistry probe pull down experiments.


Journal of Medicinal Chemistry | 2004

Substituted 3-Imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

Thomas A. Engler; James Robert Henry; Sushant Malhotra; Brian Eugene Cunningham; Kelly Wayne Furness; Joseph T. Brozinick; Timothy Paul Burkholder; Michael P. Clay; Joshua Ryan Clayton; Clive Gideon Diefenbacher; Eric Hawkins; Philip W. Iversen; Yihong Li; Terry D. Lindstrom; Angela Lynn Marquart; Johnathan Alexander Mclean; David Mendel; Elizabeth A. Misener; Daniel A. Briere; John O'Toole; Warren J. Porter; Steven Queener; Jon K. Reel; Rebecca A. Owens; Richard A. Brier; Thomas E. Eessalu; Jill R. Wagner; and Robert M. Campbell; Renee Vaughn


Bioorganic & Medicinal Chemistry Letters | 2005

The development of potent and selective bisarylmaleimide GSK3 inhibitors.

Thomas A. Engler; Sushant Malhotra; Timothy Paul Burkholder; James Robert Henry; David Mendel; Warren J. Porter; Kelly Wayne Furness; Clive Gideon Diefenbacher; Angela Lynn Marquart; Jon K. Reel; Yihong Li; Joshua Ryan Clayton; Brian Eugene Cunningham; Johnathan Alexander Mclean; John C. O’Toole; Joseph T. Brozinick; Eric Hawkins; Elizabeth A. Misener; Daniel A. Briere; Richard A. Brier; Jill R. Wagner; Robert M. Campbell; Bryan D. Anderson; Renee Vaughn; Donald B. Bennett; Timothy I. Meier; James A. Cook


Archive | 2003

Purine derivatives as kinase inhibitors

Brian R. Berridge; Joshua Ryan Clayton; Clive Gideon Diefenbacher; Thomas A. Engler; Kelly Wayne Furness; James Robert Henry; Sushant Malhotra; Angela Lynn Marquart; Johnathan Alexander Mclean; David Mendel; Timothy Paul Burkholder; Yihong Li; Jon K. Reel; Charles Edward Ruegg; John M. Sullivan


Archive | 2003

Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors

Pamela Ann Albaugh; Jochen Ammenn; Timothy Paul Burkholder; Joshua Ryan Clayton; Scott Eugene Conner; Brian Eugene Cunningham; Thomas A. Engler; Kelly Wayne Furness; James Robert Henry; Yihong Li; Sushant Malhotra; Mark Joseph Tebbe; Guoxin Zhu


Archive | 2001

Methods and compounds for treating proliferative diseases

Thomas A. Engler; Kelly Wayne Furness; Sushant Malhotra; Stephen L. Briggs; Harold B. Brooks; David K. Clawson; Concepcion Sanchez-Martinez; Faming Zhang; Guoxin Zhu


Archive | 2003

Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors

Pamela Ann Albaugh; Jochen Ammenn; Timothy Paul Burkholder; Joshua Ryan Clayton; Scott Eugene Conner; Brian Eugene Cunningham; Thomas A. Engler; Kelly Wayne Furness; James Robert Henry; Sushant Malhotra; Mark Joseph Tebbe; Guoxin Zhu; Yihong Li; Brian R. Berridge; Charles Edward Ruegg; John M. Sullivan


Archive | 2015

Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors

Marcio Chedid; Hisham Omer Eissa; Thomas A. Engler; Kelly Wayne Furness; Kenneth B. Rank; Timothy Andrew Woods; Aaron D. Wrobleski

Collaboration


Dive into the Kelly Wayne Furness's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yihong Li

Eli Lilly and Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge